Clinical trial
Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)
NCT00101582 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2005
- Completion date
- August 31, 2016
- Enrollment
- 188 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck cancer, mucositis, solid tumors, squamous cell carcinoma, stomatitis